Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
ADMINISTRATIVE POINT OF CONTACT CHANGE FOR IBUPROFEN TABLETS CONTRACT WITH EXELAN PHARMACEUTICALS. DELIVERY ORDER FOR IBUPROFEN. is a federal award for Nac Pharmaceuticals (36E797) held by Exelan Pharmaceuticals Inc. Estimated value $119K ($119K obligated). Current period of performance ends Jun 19, 2024. Place of performance: BOCA RATON FL.
ADMINISTRATIVE POINT OF CONTACT CHANGE FOR IBUPROFEN TABLETS CONTRACT WITH EXELAN PHARMACEUTICALS. DELIVERY ORDER FOR IBUPROFEN.
Recompete timing
PublicCurrent PoP ended Jun 19, 2024 (793 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordExelan Pharmaceuticals Inc — $184.3M obligated across 125 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36E79724N0021?
36E79724N0021 (Administrative POINT of contact CHANGE for) is a Nac Pharmaceuticals (36E797) award with a potential value of $119K, currently held by Exelan Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36E797-24-N-0021?
36E797-24-N-0021 is the dashed form of PIID 36E79724N0021 (Administrative POINT of contact CHANGE for), held by Exelan Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36E79724N0021?
Nac Pharmaceuticals (36E797) awarded 36E79724N0021 to Exelan Pharmaceuticals Inc (potential $119K).
Who is the incumbent on 36E79724N0021?
Exelan Pharmaceuticals Inc is the incumbent with $184.3M across 125 related awards in SCOUT’s public footprint. The current period of performance ends Jun 19, 2024.
When does Exelan Pharmaceuticals Inc’s 36E79724N0021 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 19, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.